Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
Inspire Medical Systems (INSP) announced the AMA approved new CPT codes for its Inspire V system, effective January 1, 2028. The company expects this to streamline reimbursement and expand patient access. CMS will determine Medicare payments for the new codes, with proposed valuations expected in July 2027 and final valuations in November 2027.
How this was made
The 30-second read
Why it matters
The coding approval removes a key barrier to reimbursement, likely expanding market penetration and supporting revenue growth.
Market read
A regulatory coding win that can materially improve Inspire's revenue outlook and may influence peer valuations.
What to watch
Potential delays in CMS final valuation and payer adoption timelines could slow the benefit.
Background
The AMA CPT Editorial Panel created Category I codes for Inspire V, scheduled to take effect Jan 1 2028, with CMS valuation expected in mid‑2027.
Ticker impact
Inspire Medical Systems received AMA approval for new CPT codes describing its Inspire V system, a first-time regulatory coding win.
likely upward pressure as market prices in better reimbursement outlook
Coding approval directly affects revenue potential and reduces administrative barriers, a material catalyst for the stock.
Market effects
May boost sentiment for other sleep‑apnea device makers and medical‑technology firms awaiting similar coding updates.
U.S. healthcare reimbursement landscape sees a new precedent for neurostimulation therapies.
Limited to U.S. markets; foreign peers could see indirect pressure if they seek comparable coding.
Counterpoint
If CMS valuation of the new codes is low, the anticipated revenue uplift could be muted.
Key entities
- ExecutiveTim Herbert
CEO of Inspire Medical Systems, quoted on the approval.
- Regulatory BodyAmerican Medical Association (AMA)
Approved the new CPT codes.
